- Combination Therapy
- Monotherapy
BCL-2 (B-cell lymphoma 2) Inhibitor Market was valued at USD 2,768.7 million in 2023 and is poised to grow at a 12.9% CAGR from 2024 to 2030. BCL-2 is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. With the rising prevalence of haematological cancer worldwide the demand for B-cell lymphoma 2 (Bcl-2) increased.
According to the leukemic & Lymphoma Society, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma, an estimated combined total of 186,400 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021, new cases of leukemia, lymphoma and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases that will be diagnosed in the US in 2021, the large number from the journal shows high extensive for B-cell lymphoma 2 (Bcl-2) inhibitors which drives the market. The increasing population of geriatric patients worldwide has escalated the BCL-2 market; drugs reached a large stage of development gradually impacting on growth of the market consequences resulting in lucrative opportunities in the market. Pharmaceutical companies and research organizations are continuously growing on novel drug development, but government regulations and clinical trials approval hinder the market growth which become major restraints in the B-cell lymphoma 2 (Bcl-2) inhibitor market. Geographically, North America held the major market share in 2022 and is expected to dominate the global BCL-2 market in the forecasted years due to global key players in this region.
BCL-2 (B-cell lymphoma 2) Inhibitor Market Key Developments:
- In June 2022, Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
- In April 2021, the U.S. Food and Drug Administration (FDA) announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of blood cancer. The current approval is based in part on the findings of small research that found that idecabtagene vicleucel (ide-cel) reduced tumor size in 72 percent of patients. These effects persisted on average for 11 months.
BCL-2 Inhibitor Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.9%
Largest Market
North America
Fastest Growing Market
North America
BCL-2 Inhibitor Market Dynamics
The increasing prevalence of hematological diseases across the world is the major market driver in the BCL-2 Inhibitor Market during the forecast period. Blood cancer has become common among geriatric patients because it affects blood cells. Leukemia, lymphoma, and myeloma are some of the most common types of blood cancer. With the advanced development of novel drugs and continued approach towards health awareness in public about blood cancers, BCL-2 inhibitor drugs such as venetoclax and navitoclax selectively induce apoptosis in malignant cells reducing the risk factor, also increasing the demand for such drugs in the market which drives the market growth with significant growth.
Asia-Pacific Got Significant Share Of
BCL-2 Inhibitor Market Regional Analysis
The BCL-2 Inhibitor Market in the Asia Pacific is likely to hold a significant revenue share in 2022. It is attributed to the increasing number of hematological disorders and rapidly growing well-developed healthcare expenditure escalate the market growth, increasing penetration of novel drugs and government initiatives rise the market growth. China, India, and Japan are the emerging markets for blood cancer treatment rising government enterprises for awareness and promotion accelerate the market growth for BCL-2 inhibitors. North America holds a major market share of about 55%, this is due to the greater geriatric population's escalating demand for blood cancer treatment in the region, government regulations, and well-developed high healthcare infrastructure it is expected to dominate the market in the upcoming years.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The BCL-2 Inhibitor Market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
BCL-2 Inhibitor Market Segmentation
By Product Type
By Type
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic leukemia
- Mantle Cell Lymphoma
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The BCL-2 Inhibitor Market size was valued at USD 2,768.7 million in 2023.
The BCL-2 Inhibitor Market is poised to grow at a significant CAGR of 12.9% from 2024 to 2030.
The leading players in the BCL-2 Inhibitor Market are Abcam plc, Amgen Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servie, Biorbyt Ltd., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio-Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, and Merck & Co. Inc.
| 1.Executive Summary |
| 2.Global BCL-2 Inhibitor Market Introduction |
| 2.1.Global BCL-2 Inhibitor Market - Taxonomy |
| 2.2.Global BCL-2 Inhibitor Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Product Type |
| 2.2.3.Geography |
| 2.2.4.Region |
| 3.Global BCL-2 Inhibitor Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global BCL-2 Inhibitor Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global BCL-2 Inhibitor Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Diffuse Large B-cell Lymphoma |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Follicular Lymphoma |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Chronic Lymphocytic leukemia |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Mantle Cell Lymphoma |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global BCL-2 Inhibitor Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Combination Therapy |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Monotherapy |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global BCL-2 Inhibitor Market By Geography, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. The Asia Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global BCL-2 Inhibitor Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America BCL-2 Inhibitor Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Diffuse Large B-cell Lymphoma |
| 9.1.2.Follicular Lymphoma |
| 9.1.3.Chronic Lymphocytic leukemia |
| 9.1.4.Mantle Cell Lymphoma |
| 9.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Combination Therapy |
| 9.2.2.Monotherapy |
| 9.3. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.North America |
| 9.3.2.Europe |
| 9.3.3.The Asia Pacific |
| 9.3.4.Latin America |
| 9.3.5.MEA |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe BCL-2 Inhibitor Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Diffuse Large B-cell Lymphoma |
| 10.1.2.Follicular Lymphoma |
| 10.1.3.Chronic Lymphocytic leukemia |
| 10.1.4.Mantle Cell Lymphoma |
| 10.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Combination Therapy |
| 10.2.2.Monotherapy |
| 10.3. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.North America |
| 10.3.2.Europe |
| 10.3.3.The Asia Pacific |
| 10.3.4.Latin America |
| 10.3.5.MEA |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) BCL-2 Inhibitor Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Diffuse Large B-cell Lymphoma |
| 11.1.2.Follicular Lymphoma |
| 11.1.3.Chronic Lymphocytic leukemia |
| 11.1.4.Mantle Cell Lymphoma |
| 11.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Combination Therapy |
| 11.2.2.Monotherapy |
| 11.3. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.North America |
| 11.3.2.Europe |
| 11.3.3.The Asia Pacific |
| 11.3.4.Latin America |
| 11.3.5.MEA |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) BCL-2 Inhibitor Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Diffuse Large B-cell Lymphoma |
| 12.1.2.Follicular Lymphoma |
| 12.1.3.Chronic Lymphocytic leukemia |
| 12.1.4.Mantle Cell Lymphoma |
| 12.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Combination Therapy |
| 12.2.2.Monotherapy |
| 12.3. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.North America |
| 12.3.2.Europe |
| 12.3.3.The Asia Pacific |
| 12.3.4.Latin America |
| 12.3.5.MEA |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America BCL-2 Inhibitor Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Diffuse Large B-cell Lymphoma |
| 13.1.2.Follicular Lymphoma |
| 13.1.3.Chronic Lymphocytic leukemia |
| 13.1.4.Mantle Cell Lymphoma |
| 13.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Combination Therapy |
| 13.2.2.Monotherapy |
| 13.3. Geography Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.North America |
| 13.3.2.Europe |
| 13.3.3.The Asia Pacific |
| 13.3.4.Latin America |
| 13.3.5.MEA |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abcam plc |
| 14.2.2.Amgen Inc. |
| 14.2.3.Novartis AG |
| 14.2.4.Santa Cruz Biotechnology Inc. |
| 14.2.5.Seagen Inc. |
| 14.2.6.Servie |
| 14.2.7.Biorbyt Ltd. |
| 14.2.8.Ascentage Pharma Group International |
| 14.2.9.AstraZeneca Plc |
| 14.2.10.BeiGene Ltd. |
| 14.2.11.Bio Techne Corp. |
| 14.2.12.Biorbyt Ltd. |
| 14.2.13.Bristol Myers Squibb Co. |
| 14.2.14.Hoffmann La Roche Ltd. |
| 14.2.15.Ipsen Pharma |
| 14.2.16.Merck and Co. Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Abcam plc
- Amgen Inc.
- Novartis AG
- Santa Cruz Biotechnology Inc.
- Seagen Inc.
- Servie
- Biorbyt Ltd.
- Ascentage Pharma Group International
- AstraZeneca Plc
- BeiGene Ltd.
- Bio Techne Corp.
- Biorbyt Ltd.
- Bristol Myers Squibb Co.
- Hoffmann La Roche Ltd.
- Ipsen Pharma
- Merck and Co. Inc.